CCL3 and Parkinson disease: This AS activation strategy stems from a recent discovery made by our research team, identifying a 6‐fold upregulation of CCL3 in the VMB of PD mice, in vivo, during nigrostriatal degeneration and self‐recovery, whereby reactive AS were defined as the key components of DAergic neurorescue pathways against MPTP/MPP+ injury.[94] In contrast, CCL3 did not increase EV secretion from STR‐ and ΔVS‐AS.